Shopping Cart
Remove All
Your shopping cart is currently empty
JSH-23 is an NF-κB inhibitor that inhibits NF-κB transcriptional activity (IC50=7.1 μM) but does not affect IκBα degradation. JSH-23 is an antioxidant with anti-inflammatory activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $36 | In Stock | In Stock | |
| 2 mg | $52 | In Stock | In Stock | |
| 5 mg | $85 | In Stock | In Stock | |
| 10 mg | $122 | In Stock | In Stock | |
| 25 mg | $197 | In Stock | In Stock | |
| 50 mg | $297 | In Stock | In Stock | |
| 100 mg | $453 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $94 | In Stock | In Stock |
| Description | JSH-23 is an NF-κB inhibitor that inhibits NF-κB transcriptional activity (IC50=7.1 μM) but does not affect IκBα degradation. JSH-23 is an antioxidant with anti-inflammatory activity. |
| Targets&IC50 | U251MG cells:56.21μM, NF-κB (RAW 264.7 cells):7.1 μM, NF-κB:7.1 μM, U-87MG cells:59.39 μM |
| In vitro | METHODS: Bone marrow macrophage BMMs were treated with JSH-23 (0.78-200 µM) for 48-96 h. Cell viability was measured by CCK-8 assay. RESULTS: JSH-23 had no detectable toxic effects at concentrations below 50 µM. [1] METHODS: Macrophages RAW 264.7 harboring the reporter gene pNF-κB-SEAP-NPT were treated with LPS (1 µg/mL) and JSH-23 (1-30 µM) for 16 days, and SEAP expression was assayed to reflect NF-κB transcriptional activity. RESULTS: JSH-23 inhibited LPS-induced SEAP expression in a dose-dependent manner by 23±3% at 3 µM, 68±3% at 10 µM, and 103±4% at 30 µM. JSH-23 inhibited NF-κB transcriptional activity. [2] |
| In vivo | METHODS: To investigate the role in diabetic neuropathy, JSH-23 (1-3 mg/kg) was administered orally to streptozotocin-induced diabetic rats once daily for two weeks. RESULTS: JSH-23 treatment significantly reversed nerve conduction and nerve blood flow deficits in diabetic animals. The treatment also partially corrected the reduced mechanical pain threshold.JSH-23 treatment inhibited nuclear translocation of the p65/p50 subunit in the sciatic nerve. [3] |
| Kinase Assay | Measurement of NF-κB transcriptional activity: Macrophages RAW 264.7 transfected stably with reporter plasmid of pNF-κB-SEAP-NPT are treated with 1 μg/ml LPS and/or sample for 16 hours. As the reporter, SEAP activity in the cell-free culture media is measured as followed. Single cell-derived stable transfectants are plated in 5 ml of T-25 flask, and the media is decanted 24 h later. At this time, cells are washed twice with phosphate-buffered saline, and incubations are initiated by addition of new media. Chemicals are added to the culture medium after 24 h of incubations. Aliquots (25 ml) of medium from a control or chemical-treated cultures are taken at 0, 3, 20, 24, 48, and 72 h, heated at 65°C for 5 min to eliminate the alkaline phosphatase activity, and used immediately or stored at -20°C. Mixtures consisting of dilution buffer (25 ml), assay buffer (97 ml), culture media (25 ml), and 4-methylumbelliferyl phosphate (MUP, 1 mM, 3 ml) in each well of the 96-well plates are incubated for 60 min in the dark at room temperature. Fluorescence emits the product of the SEAP/MUP is measured at 449 nm using a 96-well plate fluorometer after excitation at 360 nm. |
| Cell Research | Macrophages RAW 264.7 are incubated with various concentrations of JSH-23 compound for 24 h. The cells are treated with WST-1 solution and absorbance is measured at 450 nm.(Only for Reference) |
| Molecular Weight | 240.34 |
| Formula | C16H20N2 |
| Cas No. | 749886-87-1 |
| Smiles | Cc1ccc(NCCCc2ccccc2)c(N)c1 |
| Relative Density. | 1.086g/cm3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 255 mg/mL (1061 mM), Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: 16 mg/mL (66.57 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (20.8 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.